RBC Capital analyst Conor McNamara maintained a Buy rating on Avantor (AVTR – Research Report) on April 26 and set a price target of $30.00. The company’s shares closed last Friday at $23.94.
McNamara covers the Healthcare sector, focusing on stocks such as Danaher, QuidelOrtho, and Thermo Fisher. According to TipRanks, McNamara has an average return of -11.9% and a 30.53% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Avantor with a $28.11 average price target, a 17.42% upside from current levels. In a report released today, Barclays also maintained a Buy rating on the stock with a $28.00 price target.
The company has a one-year high of $26.16 and a one-year low of $16.63. Currently, Avantor has an average volume of 5.4M.
Based on the recent corporate insider activity of 57 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AVTR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Avantor (AVTR) Company Description:
Avantor, Inc. is a provider of mission critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. It sells materials & consumables, equipment & instrumentation and services & specialty procurement. It operates in more than 30 countries and deliver an extensive portfolio of products and services. The company was founded by John Townsend Baker in 1904 and is headquartered in Radnor, PA.
